Energy & Endurance
MOTS-c
← Back to Library
Site-only / unverified FDA safety flag Site-only / unverified Mitochondrial Metabolic
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 10, 40 mg
Dosing window: Pre-Workout
Receptor / target: AMPK
Properties: Not stated
Pre-mixed: No
Site-sourced protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 5mg 1x weekly | Inject subcutaneously 30-45 minutes pre-workout. |
| Weeks 5-8 | 5mg 2x weekly | Split doses evenly (e.g., Monday/Thursday) pre-workout. |
Site-provided protocol; not independently verified as label dosing unless graded otherwise on this page.
Alternative: Endurance Athletes
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 10mg 1x weekly | High-dose protocol utilized leading up to extreme endurance events. |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 200 mcg | Inject once daily subcutaneously. |
| Weeks 3-4 | 400 mcg | Inject once daily subcutaneously. |
| Weeks 5-6 | 600 mcg | Inject once daily subcutaneously. |
| Weeks 7-8 | 800 mcg | Inject once daily subcutaneously. |
| Weeks 9-10+ | 1,000 mcg | Inject once daily subcutaneously. |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 3
| Timeframe | Dose | Notes |
|---|---|---|
| 40-80 days | 5 mg 1x Daily every 5 days |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 4
| Timeframe | Dose | Notes |
|---|---|---|
| 8-10 weeks | 3 mg 1x Daily every 3 days |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Energy protocols are usually about mitochondrial or metabolic signaling. The logic is timing around meals/training, avoiding late-day stimulation, and watching sleep, glucose, blood pressure, and overtraining signals. Entry context: target (AMPK); route Subcutaneous; timing Pre-Workout. Site-only/low dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit.
Independent evidence
Independent safety notes: FDA lists MOTs-C among withdrawn nominated bulk substances with no identified human exposure data and insufficient safety information.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any site-sourced storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (site-sourced)
- Severe cardiovascular disease or unstable cardiac conditions: MOTS-c's AMPK activation drives an intense metabolic demand similar to vigorous exercise; subjects unable to tolerate the cardiovascular load of physical exertion should not use MOTS-c. Site-only / unverified
- Active malignancy: AMPK pathway activation has complex effects on cancer cell metabolism; MOTS-c's nuclear translocation and gene regulatory activity in cancer cells is not characterized; use in active cancer is not established. Site-only / unverified
- Insulin therapy or sulfonylurea use without clinical supervision: MOTS-c activates GLUT4 expression and increases muscle glucose uptake via AMPK, which combined with exogenous insulin or insulin secretagogues creates a meaningful additive hypoglycemia risk. Site-only / unverified
- Metformin use: metformin also activates AMPK (through complex I inhibition); overlapping AMPK stimulation effects are not characterized; monitor blood glucose closely if combining. Site-only / unverified
- Beta-blocker therapy: beta-blockers mask the adrenergic warning signs (tachycardia, tremor) of hypoglycemia; in conjunction with MOTS-c's glucose-lowering AMPK activity, this is a meaningful safety concern. Site-only / unverified
- Pregnancy: MOTS-c modulates mitochondrial gene expression; safety during fetal development is entirely unknown. Site-only / unverified
- Breastfeeding: no data. Site-only / unverified
- Pediatric use: no safety or developmental data established. Site-only / unverified
- Known hypersensitivity to MOTS-c or peptide excipients. Site-only / unverified
- Athletes competing under WADA anti-doping regulations: MOTS-c is on the WADA Prohibited List. Site-only / unverified
Side effects (site-sourced)
- Hypoglycemia when dosed fasted without exercise: the most practically significant adverse effect; AMPK activation drives aggressive glucose uptake and fatty acid oxidation in muscle; without the energy demand of physical activity, blood glucose can drop significantly; always dose pre-workout, never fasted without planned exercise. Site-only / unverified
- Injection site reactions: redness, soreness, itching at subcutaneous site; the most commonly reported adverse effect in research and anecdotal use. Site-only / unverified
- Transient fatigue and flu-like symptoms in the first days of use: as the metabolic programs are initially activated; typically resolves within the first week. Site-only / unverified
- Mild flushing: sensation of warmth; related to increased metabolic rate and peripheral vasodilation from improved tissue perfusion. Site-only / unverified
- Gastrointestinal disturbances: mild nausea, diarrhea reported in a small subset of research subjects; usually early-cycle. Site-only / unverified
- Headache: mild; uncommon; mechanism not characterized. Site-only / unverified
- Potential AMPK overstimulation: theoretical; excessive AMPK activation suppresses mTOR signaling, which while broadly pro-longevity, may impair muscle protein synthesis recovery after intense training if MOTS-c is dosed immediately post-workout. Site-only / unverified
- No hormonal side effects: MOTS-c has no known activity at androgen, estrogen, or GH axis receptors. Site-only / unverified
- Injection site infection risk from non-sterile research chemical sourcing: an acknowledged risk with all unregulated research peptides; sterile technique is paramount. Site-only / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
5-Amino-1MQSS-31 (Elamipretide)HumaninNAD+AICARL-Carnitine (Injectable)SLU-PP-332Erythropoietin (EPO)
Reported contraindicated combinations:
None listed.